General Information of Drug-Metabolizing Enzyme (DME ID: DME0028)
DME Name Cholesterol 24-hydroxylase (CYP46A1), Homo sapiens DME Info
UniProt ID
CP46A_HUMAN
EC Number    EC: 1.14.14.25     (Click to Show/Hide the Complete EC Tree)
Oxidoreductase
Oxygen paired donor oxidoreductase
Flavin/flavoprotein donor oxidoreductase
EC: 1.14.14.25
Lineage    Species: Homo sapiens     (Click to Show/Hide the Complete Species Lineage)
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Interactome
Disease Specific Interactions between Host Protein and DME (HOSPPI)
      ICD Disease Classification 05 Endocrine/nutritional/metabolic diseases
               ICD-11: 5C56 Niemann-Pick disease type C Click to Show/Hide the Full List of HOSPPI:        1 HOSPPI
                     Histone modification
                            Histone deacetylases (HDACs) Niemann-Pick disease type C Repression
Uniprot ID
HDAC1_HUMAN
Interaction Name HDACs-CYP46A1 interaction [1]
Studied Cell Lines Niemman-Pick type C patients
Description Histone deacetylases (HDACs) are reported to deacetylate the CYP46A1 gene and thereby repress the transcriptional activity of the drug-metabolizing enzyme Cholesterol 24-hydroxylase. As a result, the interaction between HDACs and CYP46A1 can inhibit the drug-metabolizing process of Cholesterol 24-hydroxylase.
      ICD Disease Classification 08 Nervous system diseases
               ICD-11: 8A20 Alzheimer disease Click to Show/Hide the Full List of HOSPPI:        1 HOSPPI
                     DNA methylation
                            DNA methyltransferase (DNMT) Alzheimer disease Significant hypermethylation
Uniprot ID
DNMT1_HUMAN
Interaction Name DNMT-CYP46A1 interaction [2]
Studied Cell Lines Brain CNS neurons
Description DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CYP46A1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Cholesterol 24-hydroxylase. As a result, the interaction between DNMT and CYP46A1 can significantly affect the drug-metabolizing process of Cholesterol 24-hydroxylase.
References
1 Histone deacetylase inhibition decreases cholesterol levels in neuronal cells by modulating key genes in cholesterol synthesis, uptake and efflux. PLoS One. 2013;8(1):e53394.
2 Chromatin-modifying agents increase transcription of CYP46A1, a key player in brain cholesterol elimination. J Alzheimers Dis. 2010;22(4):1209-21.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.